Selegiline functions by selectively inhibiting the monoamine oxidase type B enzyme. This process increases the availability of dopamine in the brain's motor pathways, helping to improve functional control and coordination in Parkinson's care.
Targeting neuronal degradation pathways, Selegiline serves as a selective monoamine oxidase-B inhibitor used in neurological care. Classified as an irreversible MAO-B inhibitor, the compound helps maintain dopamine concentrations by slowing its enzymatic breakdown. Its primary therapeutic role lies in supporting motor function when dopaminergic activity declines. The active component appears in medicines such as Eldepryl, which are prescribed for neuro-degenerative conditions.
Formulated as tablets and transdermal patches, this active compound appears in products such as Eldepryl. In Singapore, both branded and generic versions are regulated by the Health Sciences Authority, ensuring quality and consistency across manufacturers. Tablet strengths typically range from low to moderate milligram doses, while patches deliver a steady amount through the skin. Patients encounter the ingredient in single-entity products as well as fixed-dose combinations for broader symptom control.
Addressing motor fluctuations, clinicians employ the substance in managing early-stage Parkinsonian symptoms. It also assists patients experiencing gait instability or stiffness when dopaminergic therapy alone proves insufficient. Some psychiatrists explore its role in depressive disorders where traditional antidepressants show limited effect. Additionally, the agent can support individuals with mild cognitive decline by modestly enhancing neurotransmitter availability. Overall, the medication targets adults whose dopamine pathways require preservation.
Reducing the breakdown of dopamine, the medication helps sustain neurotransmitter activity in the brain. By blocking the MAO-B enzyme, it prevents the conversion of dopamine into inactive metabolites. This action leads to higher dopamine levels in synaptic clefts, which can improve movement control and mood stability. The effect develops gradually, aligning with the chronic nature of the conditions it assists.
Mild nausea, headache, or occasional dizziness may appear during the first weeks of therapy and often resolve without intervention.
Rarely, individuals experience severe hypertension, sudden loss of consciousness, or uncontrolled tremor, which warrant immediate medical attention.
Pregnant or nursing persons, as well as those with known hypersensitivity to MAO inhibitors, should avoid using the drug. Individuals with a history of severe liver disease also require caution.
Alcohol, certain antihypertensives, and other MAO-inhibiting agents can amplify adverse effects; patients should review their medication list and refer to the specific product insert for a complete interaction profile.
Storing tablets in a cool, dry place helps preserve stability over the treatment course. Treatment duration varies; some patients use the medication for short-term symptom relief, while others continue long-term under clinical supervision. Formulation differences, such as immediate-release tablets versus extended-release patches, influence how often the product is taken. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This educational overview of Selegiline is not medical advice; individual medicines such as Eldepryl differ in strength, formulation, and instructions; the provider disclaims liability for any clinical application; patients should refer to the specific medication labeling and consult a licensed healthcare professional for personalized guidance.
